The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That changed after a special on weight loss with experts and clinicians that she taped in July 2023. The panel discussion left her with her “biggest aha moment” about the medication.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

"All these years I thought that thin people -- those people -- just had more willpower," Winfrey said on her podcast.

Oprah Winfrey is facing a backlash after making claims about "thin people". The TV queen is being criticised on social media after revealing her new theory on appetite, in light of her experience using a weight-loss drug to shed pounds.

Oprah Winfrey is opening up about how using weight-loss drugs (like Ozempic, Wegovy and Mounjaro) has impacted the way she views others as well as herself. For a recent episode of The Oprah Podcast, Oprah chatted with endocrinologist and associate professor at the Yale School of Medicine Dr.